This Week in HIV Research: A Long-Acting Popularity Contest

This Week in HIV Research: A Long-Acting Popularity Contest

1 of 5
Next >

This may be the last edition of This Week in HIV Research we'll publish in 2018, but we're still going strong as we hit the home stretch. This week's slate of four recently published HIV-related studies features these findings:

  • Think the most popular form of long-acting HIV treatment is the one with least-frequent dosage? Think again.
  • Telehealth may be a valuable tool in improving HIV pre-exposure prophylaxis (PrEP) uptake among young men of color who have sex with men.
  • PrEP awareness and usage remain extremely low among cisgender women in Rhode Island.
  • When it comes to assessing the neurocognitive benefits of switching off of efavirenz (Sustiva, Stocrin), the form of measurement really matters.

Join us for one final dive into these weekly study recaps before we ring in the new year. And when you're done, be sure to read our analysis of the top 10 HIV clinical developments of 2018 by David Alain Wohl, M.D. To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: Ingram Publishing via Thinkstock

This may be the last edition of This Week in HIV Research we'll publish in 2018, but we're still going strong as we hit the home stretch. This week's slate of four recently published HIV-related studies features these findings:

  • Think the most popular form of long-acting HIV treatment is the one with least-frequent dosage? Think again.
  • Telehealth may be a valuable tool in improving HIV pre-exposure prophylaxis (PrEP) uptake among young men of color who have sex with men.
  • PrEP awareness and usage remain extremely low among cisgender women in Rhode Island.
  • When it comes to assessing the neurocognitive benefits of switching off of efavirenz (Sustiva, Stocrin), the form of measurement really matters.

Join us for one final dive into these weekly study recaps before we ring in the new year. And when you're done, be sure to read our analysis of the top 10 HIV clinical developments of 2018 by David Alain Wohl, M.D. To beat HIV, you have to follow the science!

Barbara Jungwirth is a freelance writer and translator based in New York. Follow Barbara on Twitter: @reliabletran.

Myles Helfand is the executive editor and general manager of TheBody and TheBodyPRO. Follow Myles on Twitter: @MylesatTheBody.

Image Credit: Ingram Publishing via Thinkstock